ToolGen signals aggressive CRISPR patent monetization
Gene-editing firm ToolGen announced it is entering a "harvest season" for its intellectual property, appointing a litigation expert as its new Chief Legal Officer. The move signals a more aggressive strategy to enforce and license its CRISPR-related patents. This could intensify competition, influence the formation of new patent pools, and affect SEP licensing trends for gene-editing technologies.
- ToolGen’s new Chief Legal Officer, Dave Boncheun Koo, is a US-trained litigator with over 25 years of experience, including senior roles at top Korean law firms Kim & Chang and Yulchon. His appointment is a clear move to leverage his track record in high-stakes disputes for global conglomerates to drive royalty income. - A key front for this new strategy is the ongoing series of patent infringement lawsuits filed in 2025 against Vertex Pharmaceuticals. These suits, filed in the U.S., U.K., and the Netherlands, allege that the world's first approved CRISPR-based therapy, Casgevy, infringes on ToolGen's foundational patents. - The company is specifically monetizing its portfolio related to the CRISPR-Cas9 RNP (Ribonucleoprotein) platform. This technology, which delivers the Cas9 gene editor directly as a protein complex, is considered a next-generation improvement for efficiency and safety over earlier methods. - This aggressive enforcement occurs amidst a complex global patent landscape where developers often need licenses from multiple key players, including the Broad Institute, the CVC group (University of California, University of Vienna, and Emmanuelle Charpentier), and ToolGen, to ensure freedom to operate. - The fragmented and contentious nature of CRISPR patents has led to discussions around patent pools to simplify licensing, similar to those in the digital video (MPEG-2) and telecom sectors. However, a past CRISPR patent pool initiative by VIA Licensing is now inactive, highlighting the difficulty of achieving consensus among major patent holders. - In the long-running U.S. patent interference proceedings to determine the original inventor of CRISPR technology in eukaryotic cells, the U.S. Patent Trial and Appeal Board (PTAB) has designated ToolGen as the "senior party" over rivals like the Broad Institute and CVC, giving it a statistically favorable position. - The new legal strategy will run parallel to concluding these U.S. Interference proceedings, where a definitive win would cement the foundational nature of ToolGen's patents and significantly strengthen its licensing negotiation position worldwide.
